Survey
Quarterly Survey: ALS Treatments and Biogen's Qalsody (tofersen) October 2024
Ticker(s): BIIB, Amylyx Pharmaceuticals, Mitsubishi Tanabe Pharma AmericaThe survey includes 20 neurological disease specialists.
How many patients with ALS do you have under your care?
How many SOD1-ALS patients are in your practice?
How familiar are you with Qalsody (tofersen) and the data to date?
How would you best describe your practice?
How many of your SOD1-ALS patients do you consider eligible for Qalsody (tofersen)?
How many of your SOD1-ALS patients do you currently prescribe Qalsody (tofersen)?
How many of your SOD1-ALS patients started Qalsody (tofersen) in the last 30 days?
How many of your SOD1-ALS patients discontinued Qalsody (tofersen) in the last 30 days?
How many of your SOD1-ALS patients do you expect to start Qalsody (tofersen) in the next 30 days:
What percentage (%) of your SOD1-ALS patients do you expect to prescribe Qalsody (tofersen)?
- In 1 year
- In 3 years
- In 5 years
How would you rate Qalsody (tofersen) on the following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Patient access
- Patient willingness to try
What barriers or challenges, if any, have you observed or do anticipate with Qalsody (tofersen)?
How does/will cost specifically impact access to Qalsody (tofersen) for patients with SOD1-ALS?
In your opinion, how effective is Qalsody (tofersen) in treating SOD1-ALS compared to other treatments? Please be specific.
What line of treatment would you consider Qalsody (tofersen) for patients with SOD1-ALS?
Do you plan to increase your use of Qalsody (tofersen)?
Why or why not? Please be specific.
Please elaborate on your view of Qalsody (tofersen). Please be specific.
On a scale 1-10 (where 1 is low and 10 is high) how excited are you for Qalsody (tofersen)?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
